Stockscreener 앱 받기
0.8851
1.01%
-0.009
전일 마감가:
$0.8941
열려 있는:
$0.91
하루 거래량:
17,511
Relative Volume:
0.25
시가총액:
$29.23M
수익:
-
순이익/손실:
$-563.30K
주가수익비율:
-4.4344
EPS:
-0.1996
순현금흐름:
$-22.23M
1주 성능:
-4.55%
1개월 성능:
-1.71%
6개월 성능:
-35.42%
1년 성능:
-56.93%
1일 변동 폭
$0.8801
$0.9399
1주일 범위
$0.88
$1.02
52주 변동 폭
$0.87
$2.61
Promis Neurosciences Inc Stock (PMN) Company Profile
명칭
Promis Neurosciences Inc
전화
416-847-6898
주소
SUITE 200, 1920 YONGE STREET, TORONTO
PMN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.885 | 29.23M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.84 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.29 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.27 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.13 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.98 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
ProMIS Neurosciences Updates Corporate Presentation in Recent 8-K Filing - Defense World
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment - Defense World
ProMIS Neurosciences Highlights Neurodegenerative Disease Focus - TipRanks
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial - MSN
ProMIS Neurosciences Issues Letter to Shareholders - Markets Insider
Crude Oil WTI (CLN25) Quote - The Globe and Mail
Crude Oil Brent (F) (QAJ23) Quote - The Globe and Mail
ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s - TipRanks
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease - The Manila Times
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - The Manila Times
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences faces Nasdaq delisting over share price - Investing.com
Nonfat Dry Milk (DFZ25) Quote - The Globe and Mail
Berkshire Hathaway Cl B (BRK-B-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 2.8% – Should You Buy? - Defense World
ProMIS Neurosciences stock hits 52-week low at $0.88 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences stock hits 52-week low at $0.88 - Investing.com
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Down 16.6% in November - Defense World
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewswire
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GREAT POINT PARTNERS LLC Acquires Shares in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc (PMN) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of $0.31, Surp - GuruFocus.com
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire
ProMIS Reports Positive Phase 1a Results for Alzheimer's Drug, Secures $30.3M Financing | PMN Stock News - StockTitan
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire
'Animal spirits' set to drive S&P 500 to 6,600 by mid-2025, Evercore says - Investing.com
Rising Revenue & Strategic Pipeline Advances Propel Biotech Growth Trajectory - Streetwise Reports
New Blood Cancer Treatment Shows Continued Response - Streetwise Reports
ProMIS Neurosciences (STU:23J0) PensionAndRetirementBenefit : €0.43 Mil (As of Jun. 2024) - GuruFocus.com
Biotech Shares Positive Phase I Data for Alzheimer's Treatment - Streetwise Reports
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
ProMIS Neurosciences Presents Positive Data from PMN310 - GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference - StockTitan
Boston Biotech Announces Novartis Collaboration - Streetwise Reports
ProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey
10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey
ProMIS Neurosciences stock hits 52-week low at $0.92 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Promis Neurosciences Inc (PMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):